Subtopic Deep Dive

← Bacteriophages and microbial interactions

Phage Therapy Against Antibiotic-Resistant Bacteria
Research Guide

What is Phage Therapy Against Antibiotic-Resistant Bacteria?

Phage therapy against antibiotic-resistant bacteria uses bacteriophages as targeted antimicrobials to treat multi-drug resistant (MDR) infections where conventional antibiotics fail.

Clinical and preclinical studies develop personalized phage cocktails for pathogens like MDR Pseudomonas aeruginosa and Staphylococcus aureus. Research optimizes delivery routes, phage production, and safety monitoring for immune responses and clearance. Over 10 papers from the list, including Chan et al. (2016, 691 citations) and Hatfull et al. (2021, 484 citations), demonstrate phage efficacy.

Curated Papers

Key Challenges

Why It Matters

Phage therapy counters rising MDR infections, such as those from Pseudomonas aeruginosa in burn wounds (Merabishvili et al., 2009, 498 citations). Chan et al. (2016) showed phages restore antibiotic sensitivity in MDR strains, enabling combination treatments. Hatfull et al. (2021) reviewed human trials treating chronic infections, reducing reliance on scarce new antibiotics amid global resistance crises (Peterson and Kaur, 2018, 957 citations).

Key Research Challenges

Phage Resistance Development

Bacteria evolve resistance to phages during therapy, limiting long-term efficacy (Oechslin, 2018, 554 citations). Cocktails mitigate this but require rapid adaptation to emerging mutants. Balancing lytic phage selection against resistance evolution remains critical (Chan et al., 2016).

Phage Formulation Stability

Phages degrade during storage and delivery without proper encapsulation (Malik et al., 2017, 524 citations). Clinical trials demand stable formulations for intravenous or topical use. Scale-up from lab to GMP production challenges purity and viability (Merabishvili et al., 2009).

Host Range Optimization

Phages must target specific MDR strains without lysing commensal bacteria (Hyman, 2019, 492 citations). Isolation and characterization ensure broad coverage for cocktails. Clinical safety requires narrow host range to minimize immune activation (Hatfull et al., 2021).

Essential Papers

Antibiotic Resistance Mechanisms in Bacteria: Relationships Between Resistance Determinants of Antibiotic Producers, Environmental Bacteria, and Clinical Pathogens

Elizabeth Peterson, Parjit Kaur · 2018 · Frontiers in Microbiology · 957 citations

Emergence of antibiotic resistant pathogenic bacteria poses a serious public health challenge worldwide. However, antibiotic resistance genes are not confined to the clinic; instead they are widely...

Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa

Benjamin K. Chan, Mark Sistrom, John E. Wertz et al. · 2016 · Scientific Reports · 691 citations

Abstract Increasing prevalence and severity of multi-drug-resistant (MDR) bacterial infections has necessitated novel antibacterial strategies. Ideally, new approaches would target bacterial pathog...

Antibiotic alternatives: the substitution of antibiotics in animal husbandry?

Guyue Cheng, Haihong Hao, Shuyu Xie et al. · 2014 · Frontiers in Microbiology · 606 citations

It is a common practice for decades to use of sub-therapeutic dose of antibiotics in food-animal feeds to prevent animals from diseases and to improve production performance in modern animal husban...

Antimicrobial peptides: an overview of a promising class of therapeutics

Andrea Giuliani, Giovanna Pirri, Silvia Fabiole Nicoletto · 2007 · Open Life Sciences · 599 citations

Abstract Antibiotic resistance is increasing at a rate that far exceeds the pace of new development of drugs. Antimicrobial peptides, both synthetic and from natural sources, have raised interest a...

Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy

Frank Oechslin · 2018 · Viruses · 554 citations

Bacteriophage (phage) therapy, i.e., the use of viruses that infect bacteria as antimicrobial agents, is a promising alternative to conventional antibiotics. Indeed, resistance to antibiotics has b...

Epidemic multiple drug resistant <i>Salmonella</i> Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype

Robert A. Kingsley, Chisomo Msefula, Nicholas R. Thomson et al. · 2009 · Genome Research · 550 citations

Whereas most nontyphoidal Salmonella (NTS) are associated with gastroenteritis, there has been a dramatic increase in reports of NTS-associated invasive disease in sub-Saharan Africa. Salmonella en...

Formulation, stabilisation and encapsulation of bacteriophage for phage therapy

Danish J. Malik, I. J. Sokolov, Gurinder K. Vinner et al. · 2017 · Advances in Colloid and Interface Science · 524 citations

Reading Guide

Foundational Papers

Start with Merabishvili et al. (2009, 498 citations) for clinical cocktail production in burn wounds, then Cheng et al. (2014, 606 citations) on antibiotic alternatives context.

Recent Advances

Hatfull et al. (2021, 484 citations) reviews human trials; Hyman (2019, 492 citations) details isolation for therapy; Chan et al. (2016, 691 citations) shows sensitivity restoration.

Core Methods

Phage isolation and host range testing (Hyman, 2019); encapsulation for stability (Malik et al., 2017); lytic cocktail QC for trials (Merabishvili et al., 2009).

How PapersFlow Helps You Research Phage Therapy Against Antibiotic-Resistant Bacteria

Discover & Search

PapersFlow's Research Agent uses searchPapers and citationGraph to map foundational works like Chan et al. (2016, 691 citations) and its 200+ citers, revealing phage-antibiotic synergy networks. exaSearch uncovers unpublished trials on MDR Pseudomonas cocktails, while findSimilarPapers links Peterson and Kaur (2018) to therapy contexts.

Analyze & Verify

Analysis Agent applies readPaperContent to extract phage resistance rates from Oechslin (2018), then runPythonAnalysis with pandas to compute mutation frequencies across 10 papers. verifyResponse via CoVe cross-checks claims against Hatfull et al. (2021), with GRADE scoring evidence from human trials as high-quality.

Synthesize & Write

Synthesis Agent detects gaps in MDR Salmonella coverage (Kingsley et al., 2009) versus Pseudomonas focus, flagging contradictions in resistance mechanisms. Writing Agent uses latexEditText and latexSyncCitations to draft therapy protocols citing Malik et al. (2017), with latexCompile generating review figures and exportMermaid for phage-bacteria interaction diagrams.

Use Cases

"Analyze phage resistance rates in MDR Pseudomonas trials from 10 papers"

Research Agent → searchPapers('MDR Pseudomonas phage therapy') → Analysis Agent → readPaperContent(Chan 2016, Oechslin 2018) → runPythonAnalysis(pandas meta-analysis of resistance frequencies) → CSV table of mutation rates per strain.

"Write LaTeX review on phage cocktail production for clinical use"

Synthesis Agent → gap detection(Merabishvili 2009 vs recent) → Writing Agent → latexEditText(cocktail protocol) → latexSyncCitations(9 papers) → latexCompile → PDF with GMP flowchart via exportMermaid.

"Find code for phage host range prediction models"

Research Agent → paperExtractUrls(Hyman 2019) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for phage-bacteria matching, verified via runPythonAnalysis.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers(50+ on phage MDR) → citationGraph → DeepScan(7-step verification with CoVe on Hatfull 2021) → structured report on therapy efficacy. Theorizer generates hypotheses on phage-antibiotic combos from Chan 2016 data. DeepScan analyzes formulation stability across Malik 2017 and Merabishvili 2009 with statistical checkpoints.

Try Doxa for Phage Therapy Against Antibiotic-Resistant Bacteria Research

Frequently Asked Questions

What defines phage therapy for antibiotic-resistant bacteria?

Phage therapy deploys lytic bacteriophages targeting MDR pathogens like Pseudomonas aeruginosa, restoring antibiotic sensitivity (Chan et al., 2016).

What methods optimize phage cocktails?

Cocktails combine phages for broad host range (Hyman, 2019), produced via GMP small-scale methods for trials (Merabishvili et al., 2009).

What are key papers?

Chan et al. (2016, 691 citations) on sensitivity restoration; Hatfull et al. (2021, 484 citations) on clinical infections; Oechslin (2018, 554 citations) on resistance.

What open problems exist?

Phage resistance evolution (Oechslin, 2018), formulation stability (Malik et al., 2017), and scaling cocktails for diverse MDR strains (Hatfull et al., 2021).